We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+5.38%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.43B
AUM Growth
+$209M
Cap. Flow
+$182M
Cap. Flow %
12.72%
Top 10 Hldgs %
28.58%
Holding
96
New
13
Increased
36
Reduced
31
Closed
4

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$34M
2
COR icon
Cencora
COR
+$18.2M
3
TDOC icon
Teladoc Health
TDOC
+$17.4M
4
ISRG icon
Intuitive Surgical
ISRG
+$16.6M
5
MCK icon
McKesson
MCK
+$16.1M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27M
2
ABBV icon
AbbVie
ABBV
+$14.1M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.4M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.74M
5
GKOS icon
Glaukos
GKOS
+$7.91M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Industrials 0.98%
3 Technology 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOV
76
DELISTED
Myovant Sciences Ltd.
MYOV
$4.63M 0.32%
225,000
+25,000
+13% +$569K
STXS icon
77
Stereotaxis
STXS
$143M
$4.6M 0.32%
684,402
+120,002
+21% +$712K
IMGN
78
DELISTED
Immunogen Inc
IMGN
$4.46M 0.31%
+550,000
New +$4.49M
ARNA
79
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.16M 0.29%
60,000
-10,000
-14% -$769K
NUAN
80
DELISTED
Nuance Communications, Inc.
NUAN
$3.93M 0.27%
+90,000
New +$4.14M
ALKS icon
81
Alkermes
ALKS
$8.23B
$3.91M 0.27%
209,354
– –
AMWL icon
82
American Well
AMWL
$227M
$3.37M 0.24%
9,708
+6,708
+224% +$3.64M
IONS icon
83
Ionis Pharmaceuticals
IONS
$9.35B
$3.37M 0.24%
+75,000
New +$4.18M
VRAY
84
DELISTED
ViewRay, Inc.
VRAY
$3.37M 0.24%
775,000
– –
PHR icon
85
Phreesia
PHR
$771M
$3.13M 0.22%
+60,000
New +$3.78M
GKOS icon
86
Glaukos
GKOS
$10.7B
$2.94M 0.2%
35,000
-90,000
-72% -$7.91M
GDRX icon
87
GoodRx Holdings
GDRX
$1.29B
$2.93M 0.2%
75,000
+40,000
+114% +$1.8M
VEEV icon
88
Veeva Systems
VEEV
$38.4B
$2.87M 0.2%
+11,000
New +$3.06M
NXGN
89
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
$2.71M 0.19%
+150,000
New +$2.96M
DCPH
90
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.69M 0.19%
60,000
– –
EPZM
91
DELISTED
Epizyme, Inc
EPZM
$2.31M 0.16%
265,000
– –
PVLA
92
Palvella Therapeutics
PVLA
$2.22B
$771K 0.05%
3,750
– –
AGIO icon
93
Agios Pharmaceuticals
AGIO
$1.99B
– –
-130,000
Closed -$5.63M
AUPH icon
94
Aurinia Pharmaceuticals
AUPH
$2.06B
– –
-125,000
Closed -$1.73M
FPRX
95
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-250,000
Closed -$4.25M
CTIC
96
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-300,000
Closed -$966K
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Rhenman & Partners Asset Management held 96 positions worth $1.43B, up 17% from $1.23B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $182M of net new capital in Q1 2021, opening 13 new positions and adding to 36 existing holdings. Its largest new stake was Cencora: 167,957 shares worth $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $27M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2021 buy was Cencora: 167,957 shares worth $19.8M.
  • Rhenman & Partners Asset Management added most to Johnson & Johnson in Q1 2021, an estimated $34M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2021 reduction was BioMarin Pharmaceuticals, cutting an estimated $27M.
  • Rhenman & Partners Asset Management fully exited Agios Pharmaceuticals in Q1 2021, selling an estimated $5.63M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.43B portfolio in Q1 2021.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 4 in Q1 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 17% quarter-over-quarter to $1.43B.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2021, filed 14 May 2021.